Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA(R) (omadacycline) Across a Range of Serious Infections at IDWeek 2024
— Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that […]